Galenicum advances in developing its product pipeline

October 16, 2014

Galenicum has completed the tigecycline development process, a broad-spectrum antibiotic in the tetracycline family, with a suitable efficacy and safety profile to treat complicated intra-abdominal infections, as well as skin and soft tissue infections. The development obtained has added substantial innovations to a lyophilized –or freeze-dried– product whose attainment process is technically complex. 

Moreover, the company has obtained approval for the bioequivalence studies for rasagiline, a medication for individual use or in combination with the treatment of symptoms of Parkinson’s disease. It also received approval for anagrelide, a drug recommended for the treatment of essential thrombocythaemia or the overproduction of platelets in the blood, and for the treatment of chronic myeloid leukemia. Galenicum representatives stated that they plan to start Decentralised Procedures (DCP) for both products after Data Exclusivity expires.

With these new developments, Galenicum continues to expand its product portfolio, which will foreseeably add new products over the next months in several therapeutic areas.